This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New Strong Sell Stocks for June 24th
by Zacks Equity Research
RAD, WTRH, BNR, NMR, and VNCE have been added to the Zacks Rank #5 (Strong Sell) List on June 24, 2021
UBS, Credit Suisse (CS) Might Face Higher Liquidity Requirements
by Zacks Equity Research
The Swiss regulators are mulling to raise liquidity requirements for the country's systemically important banks, including UBS Group (UBS) and Credit Suisse (CS), to counter any downturn.
DICK'S Sporting Goods, Nomura Holdings, Apple, Garmin, Google highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
DICK'S Sporting Goods, Nomura Holdings, Apple, Garmin, Google highlighted as Zacks Bull and Bear of the Day
Bear of the Day: Nomura Holdings (NMR)
by David Borun
Steep losses and a dividend in jeopardy make this a bank stock to avoid.
UBS, Nomura (NMR) to Pay Penalty to Settle Bond-Rigging Claims
by Zacks Equity Research
UBS and Nomura (NMR) have been hit hardest by the European Commission for colluding on Euro sovereign bond trading during the financial crisis.
Nomura (NMR) Ups Profit Target Despite Incurring Archegos Loss
by Zacks Equity Research
Nomura (NMR) raises its pretax income target for the next fiscal year by 14.3% despite taking a nearly $3-billion hit from the Archegos collapse.
Credit Suisse & Others Tighten Lending Terms in Archegos Collapse
by Zacks Equity Research
Banks like Credit Suisse (CS), Morgan Stanley (MS), Nomura (NMR) and UBS Group (UBS) are tightening lending terms of some of their hedge fund clients to prevent events like the Archegos collapse.
NMR vs. SCHW: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NMR vs. SCHW: Which Stock Is the Better Value Option?
Nomura (NMR) to Conduct Investigation on Archegos-Related Loss
by Zacks Equity Research
Nomura Holdings (NMR) is reviewing deficiencies in risk management processes that resulted in the company taking about $2 billion financial hit.
Credit Suisse (CS) Expects to Report Q1 Loss on Archegos Fallout
by Zacks Equity Research
Credit Suisse (CS) projects a CHF 4.4 billion financial hit on account of the Archegos Capital Management crisis.
NMR vs. WETF: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NMR vs. WETF: Which Stock Is the Better Value Option?
Credit Suisse (CS) & Nomura (NMR) Outlook Downgraded by Moody's
by Zacks Equity Research
Deficiencies in risk management processes result in outlook downgrade for Credit Suisse Group (CS) & Nomura Holdings' (NMR) by Moody's.
Mitsubishi UFJ (MUFG) Raises Profit Guidance for FY2021
by Zacks Equity Research
Progress in business performance and improvement in securities unit led Mitsubishi UFJ (MUFG) to raise its profit target for fiscal 2021.
Credit Suisse's (CS) Outlook Downgraded on Archegos Default
by Zacks Equity Research
S&P Global Ratings downgrades outlook on Credit Suisse (CS) to negative as the Swiss bank expects to take a major financial hit on account of the Archegos Capital Management crisis.
Mitsubishi UFJ (MUFG) Expects $300M Hit From Archegos Episode
by Zacks Equity Research
The securities arm of Mitsubishi UFJ (MUFG) continues to measure the amount of loss it may experience as Archegos defaulted on its margin call.
Credit Suisse (CS), Nomura (NMR) to be Hit by Archegos' Default
by Zacks Equity Research
First-quarter results of Credit Suisse (CS) and Nomura (NMR) will likely reflect the impact of Archegos defaulting on its margin call.
Stock Market News for Mar 30, 2021
by Zacks Equity Research
Markets ended mostly lower on Monday, with bank stocks tumbling on concerns of potential losses from a hedge fund after it was compelled to sell huge holdings in stocks.
Nomura (NMR): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Nomura (NMR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
NMR vs. TW: Which Stock Is the Better Value Option?
by Zacks Equity Research
NMR vs. TW: Which Stock Is the Better Value Option?
Nomura (NMR): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Nomura (NMR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
NMR vs. TW: Which Stock Is the Better Value Option?
by Zacks Equity Research
NMR vs. TW: Which Stock Is the Better Value Option?
NMR vs. TW: Which Stock Is the Better Value Option?
by Zacks Equity Research
NMR vs. TW: Which Stock Is the Better Value Option?
Nomura (NMR) to Bolster Wealth and Fixed Income Units in Asia
by Zacks Equity Research
Nomura (NMR) seeks to benefit from relatively higher interest rates in the Asian region by hiring more employees in the Wealth and Fixed Income departments.
Top Ranked Value Stocks to Buy for November 30th
by Zacks Equity Research
Here are three stocks with buy rank and strong value characteristics for investors to consider today, November 30th.
NMR vs. TW: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NMR vs. TW: Which Stock Is the Better Value Option?